

### Thursday 4<sup>th</sup> November

<b>1830 - 1930</b>	<b>Welcome &amp; Keynote Address</b>	
<i>Session Chairs: Rick Kefford (Australia)</i>		<b>Parkside Auditorium</b>
1830 - 1930	Evolving Melanoma Therapeutics	
	<u>Keith Flaherty</u>	

### Friday 5<sup>th</sup> November

<b>0715 - 0730</b>	<b>GSK Program: Adjuvant Therapy – What lies ahead</b>	
<i>Session Chairs: Richard Kefford &amp; Peter Hersey</i>		<b>Parkside 110A &amp; 110B</b>
0715 - 0730	What is the promise and risk of selective BRAF inhibitors in adjuvant therapy?	
	<u>Lead discussants: Jeff Sosman, Reinhard Dummer</u>	
0730 - 0745	How can we target immunotherapy more effectively? Biomarker studies	
	<u>Lead discussants: Jonathan Cebon, Graham Mann, John Kirkwood</u>	
0745 - 0800	What lies ahead in choice of antigens for immunotherapy?	
	<u>Lead discussants: Rod Dunbar, Jurgen Becker</u>	
0800 - 0815	Questions and Discussion	
<b>0830 - 1030</b>	<b>Targeted Therapies I</b>	
<i>Session Chairs: Dirk Schadendorf (Germany) &amp; Rod Dunbar (New Zealand)</i>		<b>Parkside Auditorium</b>
0830 - 0900	Selective inhibition of oncogenic BRAF V600E/K/D by GSK2118436: Evidence of clinical activity in subjects with metastatic melanoma	
	<u>Richard Kefford</u>	
0900 - 0930	An open-label, multicenter phase 2 study of continuous oral dosing of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma	
	<u>Jeff Sosman</u>	
0930 - 1000	Feedback inhibition of RAF/MEK signalling	
	<u>Neal Rosen</u>	
1000 - 1030	BRAF/CRAF switching	
	<u>Richard Marais</u>	
<b>1030 - 1100</b>	<b>Morning tea</b>	
<b>1100 - 1300</b>	<b>Melanoma Stem Cells</b>	

\* Program current as of 27 October 2010 and is subject to change.

<i>Session Chairs: Markus Frank (USA) &amp; Jonathan Cebon (Australia)</i>		<b>Parkside Auditorium</b>
1100 - 1124	Slow cycling self renewing JARID1B-positive cells are essential for long-term maintenance of malignant melanoma <i>Meenhard Herlyn</i>	
1124 - 1148	Melanoma progression <i>Mark Shackleton</i>	
1148 - 1212	Stem Cells <i>Marcus Bosenberg</i>	
1212 - 1236	Mechanisms of melanoma stem cell-driven tumor growth <i>Tobias Schatton</i>	
1236 - 1300	Human Melanoma Initiating Cells Express the Neural Crest Nerve Growth Factor p75 Receptor CD271 <i>Alexander Boiko</i>	
<b>1300 - 1400</b>	<b>BMS Lunch Symposium</b>	
<i>Session Chairs: Peter Hersey (Australia)</i>		<b>Parkside 110A &amp; B Combined</b>
1300 - 1305	Introduction <i>Peter Hersey</i>	
1305 - 1320	Cancer Vaccines. Successes and failures <i>Jonathan Cebon</i>	
1320 - 1340	Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 <i>F. Stephen Hodi</i>	
	Discussion	
<b>1400 - 1530</b>	<b>Animal Models</b>	
<i>Session Chairs: Lionel Larue (France) &amp; Graeme Walker (Australia)</i>		<b>Parkside Auditorium</b>
1400 - 1418	Interferon- links UV to melanocyte activation and promotes melanomagenesis <i>Glenn Merlino</i>	
1418 - 1436	Determinants of melanoma progression identified from a series of transgenic zebrafish <i>Adam Hurlstone</i>	
1436 - 1454	BRAF zebrafish <i>Liz Patton</i>	

1454 - 1512	A murine model for de novo melanoma	
	<u>Masashi Kato</u>	
1512 - 1530	p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation	
	<u>Neil Box</u>	
<b>1530 - 1600</b>	<b>Afternoon Tea</b>	
<b>1600 - 1730</b>	<b>Cell Growth Regulation</b>	
<i>Session Chairs: Dot Bennett (UK) &amp; Wolfgang Weninger (Australia)</i>		<b>Parkside Auditorium</b>
1600 - 1618	A Wnt-ery response to genotoxic injury: Effects of Wnt5A on cell cycle, p21 and DNA repair.	
	<u>Ashani Weeraratna</u>	
1618 - 1636	BRAF-regulated targets in cell proliferation and apoptosis: Implications for therapeutic resistance	
	<u>Andrew Aplin</u>	
1636 - 1654	UVR-induced DNA damage checkpoint	
	<u>Brian Gabrielli</u>	
1654 - 1712	Real-time Imaging of Cell Cycle Progression in Melanoma	
	<u>Nikolas Haass</u>	
1712 - 1730	<u>TBC</u>	
	<u>TBC</u>	
<b>1730 - 1830</b>	<b>Poster Session A</b>	

### Saturday 6<sup>th</sup> November

<b>0830 - 1030</b>	<b>Targeted Therapies II</b>	
<i>Session Chairs: Christoph Hoeller (Austria) &amp; Paul Chapman (USA)</i>		<b>Parkside Auditorium</b>
0830 - 0900	PARP and MEK inhibitors	
	<u>Mark Middleton</u>	
0900 - 0930	Understanding intrinsic and acquired resistance to BRAF inhibitors in melanoma	
	<u>Keiran Smalley</u>	
0930 - 1000	AZD6244 and development of resistance	
	<u>Reinhard Dummer</u>	
1000 - 1030	Induction of apoptosis in melanoma cells by inhibitors of mutated BRAF. The key to therapeutic success?	
	<u>Peter Hersey</u>	

\* Program current as of 27 October 2010 and is subject to change.

<b>1100 - 1300</b>	<b>Targeted Therapies III</b>	
<i>Session Chairs: Michael Brown (Australia)</i>		<b>Parkside Auditorium</b>
1100 - 1124	Adoptive cell transfer immunotherapy with TCR transgenic lymphocytes <i>Antoni Ribas</i>	
1124 - 1148	Tumor immunology meets tumor biology: Understanding how progressively growing autochthonous melanomas evade vaccine-induced T cell responses in genetically engineered mice <i>Thomas Tueting</i>	
1148 - 1212	TBC <i>Grant McArthur</i>	
1212 - 1236	Adaptation to ER Stress as a Mechanism of Resistance of Melanoma to Treatment <i>X. D. Zhang</i>	
1236 - 1300	Transcriptional modules predict MEK addiction and response to selumetinib (AZD6244) <i>Jonathan. Dry</i>	
<b>1300 - 1400</b>	<b>Lunch</b>	
<b>1300 - 1400</b>	<b>Advanced Melanoma – Finding a Tailored Solution for Patients (Roche Symposium)</b>	
<i>Session Chairs: Richard Kefford (Australia)</i>		<b>Parkside 110A</b>
1300 - 1305	Opening Remarks <i>Richard Kefford</i>	
1305 - 1315	The Evolution of Treatment for Advanced Melanoma: From Chemotherapy to Individualized Targeted Therapies <i>Axel Hauschild</i>	
1315 - 1325	Pivotal Signal Transduction Pathways in Melanoma <i>Grant McArthur</i>	
1325 - 1340	Advances in RAF Pathway Inhibitors for Advanced Melanoma <i>Jeffrey Sosman</i>	
1340 - 1350	Q&A and Closing Remarks	
<b>1400 - 1530</b>	<b>Cell &amp; Tumour Biology I</b>	
<i>Session Chairs: Helmut Schaidler (Austria) &amp; Kiarash Khosrotehrani (Australia)</i>		<b>Parkside 110A</b>
1400 - 1413	p16INK4A regulates G0-G1 entry and promotes apoptosis via CDK3/CCNC <i>D. Hogg</i>	

1400 - 1530	1413 - 1426	Bone morphogenetic protein and nodal regulate adhesion and migration in melanoma cells and confer a malignant phenotype to melanocytes <u>C. Busch</u>
	1426 - 1439	Metastatic melanoma and breast cancer cells with imposed glycolytic metabolism fail to metastasize <u>M. Berridge</u>
	1439 - 1452	GLI2, a new marker of melanoma progression? <u>A. Mauviel</u>
	1452 - 1505	Loss of E-cadherin increases metastatic potential of melanoma <u>L. Larue</u>
	1505 - 1518	Long-Term Exposure to the B-RAFV600E Inhibitor PLX4720 Results in Melanoma Cells with Increased Activation of ERK1/2 and High Proliferation Potential <u>F. Lai</u>
	1518 - 1531	NR4A nuclear receptors link MC1R signalling to melanocytic cytoprotection. <u>A. Smith</u>
	<b>1400 - 1530</b>	<b>Preclinical Studies I</b>
	Session Chairs: <i>Jeffrey Lee (USA) &amp; Barbara Bedogni (USA)</i> <span style="float: right;"><b>Parkside 110B</b></span>	
1400 - 1530	1400 - 1413	Cell Senescence in Cell-Based Screening for Melanoma/Cancer Drug Discovery <u>D. Bennett</u>
	1413 - 1426	Targeting XIAP to increase endoplasmic reticulum stress-induced apoptosis for melanoma therapy <u>D. Hill</u>
	1426 - 1439	Metastatic melanoma cells are sensitive to drugs inducing endoplasmic reticulum stress-mediated apoptosis <u>D. Beck</u>
	1439 - 1452	Inhibition of the EGF-receptor as a pharmacological strategy in treatment regimen for metastatic melanoma - data from preclinical models <u>C. Hoeller</u>
	1452 - 1505	Modulation of NOXA and MCL-1 as a Tactic for Sensitizing Melanoma Cells to the BH3-mimetic ABT-737 <u>N. Mohana Kumaran</u>
	1505 - 1518	Tropomyosin Tm5NM1: A Novel Target for Melanoma Chemotherapy <u>J. Stehn</u>
	1518 - 1531	Generation of IL7-dependent melanoma-specific human T cell clones

		<i>R. Dunbar</i>	
<b>1400 - 1530</b>		<b>Microenvironment &amp; Genomics</b>	
	<i>Session Chairs: Boris Bastian (USA) &amp; Therese Becker (Australia)</i>		<b>Parkside Auditorium</b>
<b>1400 - 1530</b>	1400 - 1413	Angiotropism and extravascular migratory metastasis: Update with gene expression profiling of human primary angiotropic melanoma	
		<i>R. Barnhill</i>	
	1413 - 1426	The vascular bed, vessel stabilization and maturation affect the resistance to anti-angiogenic therapy in malignant melanoma	
		<i>I. Helfrich</i>	
	1426 - 1439	BRAF mutation, NRAS mutation and absence of an immune-related expressed gene profile predict poor outcome in surgically resected stage III melanoma	
		<i>G. Mann</i>	
	1439 - 1452	Somatic Alterations in the Melanoma Genome: A High-Resolution Array Based Comparative Genomic Hybridization Study	
		<i>R. Kumar</i>	
	1452 - 1505	Clonal tumor profiling of malignant melanoma genomes	
		<i>A. Sekulic</i>	
1505 - 1518	Genetic alterations in NRAS related pathways: identification of three distinct molecular signatures in Acral Lentiginous Melanoma		
	<i>S. Puig</i>		
1518 - 1531	Analysis of KIT, BRAF, NRAS and PDGFRA Aberrations in 565 Chinese Melanoma Patients		
	<i>Y. Kong</i>		
<b>1530 - 1600</b>		<b>Afternoon tea</b>	
<b>1600 - 1730</b>		<b>Cell &amp; Tumour Biology II</b>	
	<i>Session Chairs: Véronique Winnepenninckx (Netherlands) &amp; Helen Rizos (Australia)</i>		<b>Parkside 110A</b>
	1600 - 1613	Regulation of Melanoma Phenotype Switching.	
		<i>K. Hoek</i>	
	1613 - 1626	miR-193b regulates multiple key pathways in melanoma: A new link to Mcl-1	
		<i>V. Tron</i>	
	1626 - 1639	The pigment cell specific microRNA, miR-211, as a novel tumour suppressor for melanoma.	

1600 - 1730		<u>S. Woods</u>	
	1639 - 1652	Humans exposed to intermittent doses of simulated solar UVR show differential expression of microRNAs in their melanocytes	
		<u>M. Harter</u>	
	1652 - 1705	The role of RNA editing enzyme ADAR1 in melanoma	
		<u>MJ. Besser</u>	
	1705 - 1718	Oncogenic BRAFV600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and down-regulation of transcription repressor HES1	
		<u>V. Setaluri</u>	
	1718 - 1731	To age or to die - oncogene-induced senescence in melanocytes	
		<u>C. Leikam</u>	
<b>1600 - 1730</b>		<b>Animal Models &amp; Preclinical Studies II</b>	
	<i>Session Chairs: Ed de Fabo (USA) &amp; Marcus Bosenberg (USA)</i>		<b>Parkside 110B</b>
1600 - 1730	1600 - 1613	Neonatal UV irradiation promotes the outgrowth of UV initiated melanomas: a role or mast cell-dependent neonatal immune tolerance.	
		<u>F. Noonan</u>	
	1613 - 1626	Autochthonous primary and metastatic melanomas in Hgf-Cdk4R24C mice evade T cell-mediated immune surveillance	
		<u>J. Landsberg</u>	
	1626 - 1639	Differential roles of the pRb and p53 pathways in naevo and melanoma genesis	
		<u>G. Walker</u>	
	1639 - 1652	Development of a somatic cell gene transfer mouse model of melanoma	
		<u>S. Holmen</u>	
	1652 - 1705	Local cure of melanoma in mice and dogs by intratumoral injection of EBC46.	
		<u>G. Boyle</u>	
1705 - 1718	Targeting Circulating Tumor Cells with Nanoliposomes Containing siRNA Directed Against IL-8 Disrupts Interaction with Neutrophils and Thereby Decreases Lung Metastasis Development		
	<u>G. Robertson</u>		
	1718 - 1731	T-cell and clinical responses after therapy with murine monoclonal antibody to anti-OX40: Results from a	

		phase I clinical trial	
		<u>W. Urba</u>	
<b>1600 - 1730</b>	<b>Epidemiology &amp; Preclinical Studies III</b>		
	<i>Session Chairs: Nancy Thomas (USA) &amp; Sancy Leachman (USA)</i>		<b>Parkside Auditorium</b>
	1600 - 1613	Interaction of sun exposure and CDKN2A in the development of cutaneous melanoma	
		<u>M. Berwick</u>	
	1613 - 1626	Sunbed Use during Adolescence and Early Adulthood is Associated with Increased Risk of Early-onset Melanoma	
		<u>A. Cust</u>	
	1626 - 1639	Melanoma cases with multiple independent primary melanomas show the strongest evidence for a heritable predisposition	
		<u>L. Cannon-Albright</u>	
	1639 - 1652	Disentangling the genetic mechanisms underlying melanoma occurrence by pathway-based analysis of genome-wide data	
		<u>F. Demenais</u>	
<b>1600 - 1730</b>	1652 - 1705	Cutaneous Manifestations of the Selective BRAF Inhibitor GSK2118436.	
		<u>J. Livingston</u>	
	1705 - 1718	Chemokine mediated enhancement of melanoma immunotargeting in situ and DNA vaccination.	
		<u>V. Alexeev</u>	
	1718 - 1731	Identification of circulating malignant melanoma-initiating cells	
		<u>J. MA</u>	
<b>1730 - 1830</b>	<b>Poster Session (SMR)</b>		
<b>1730 - 1830</b>	<b>Abbott Program: Recent Advances in the Diagnosis of Melanoma</b>		
	<i>Session Chairs: Richard Scolyer</i>		<b>Parkside 110A</b>
	1730 - 1800	Targeting Immunotherapy in Patients with Melanoma	
		<u>Peter Hersey</u>	
	1800 - 1830	FISH for Melanoma diagnosis – the MSKCC experience	
		<u>Klaus Busam</u>	

**Sunday 7<sup>th</sup> November**

<b>0830 - 1030</b>	<b>Melanoma Tumour Biology</b>	
<i>Session Chairs: Kowichi Jimbow (Japan) &amp; Nikolas Haass (Australia)</i>		<b>Parkside Auditorium</b>
0830 - 0854	TBC <i>David Fisher</i>	
0854 - 0918	Autophagy <i>Maria S. Soengas</i>	
0918 - 0942	A role for ATF2 in regulating MITF and melanoma development <i>Ze'ev Ronai</i>	
0942 - 1006	Oncogene-induced melanocyte senescence <i>Helen. Rizos</i>	
1006 - 1030	Signalling and monitoring phenotype switching in melanoma cell subpopulations <i>Colin Goding</i>	
<b>1030 - 1100</b>	<b>Morning Tea</b>	
<b>1100 - 1300</b>	<b>Melanoma Gene Discovery</b>	
<i>Session Chairs: Ichiro Okamoto (Austria) &amp; Pam Pollock (Australia)</i>		<b>Parkside Auditorium</b>
1100 - 1120	Towards Deciphering the Genetic Landscape of Melanoma <i>Yardena Samuels</i>	
1120 - 1140	Next Generation Sequencing for Single Nucleotide Variant (SNV) Discovery in Melanoma <i>Ruth Halaban</i>	
1140 - 1200	Complete exome resequencing reveals inactivating mutations in a novel metastasis suppressor on chromosome 3 in uveal melanoma <i>William Harbour</i>	
1200 - 1220	GenoMEL GWAS <i>Tim Bishop</i>	
1220 - 1240	An Australian Genome-Wide Association Study to Identify Melanoma Predisposition Genes <i>Nick Hayward</i>	
1240 - 1300	Melanoma predisposition gene discovery using a genome-wide sequencing approach <i>Kevin Brown</i>	
<b>1300 - 1400</b>	<b>SMR Congress Awards and Close</b>	

\* Program current as of 27 October 2010 and is subject to change.